The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...

Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...

A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American ...

Killer immune cells destroy cancer cells and cells infected by virus. These CD8 + T cells are activated after detection of viral infection or growth of “non-self” tumor cells. However, in chronic ...

For his work towards developing a novel cancer immunotherapy that turns tumors into their own vaccines, Fábio Rosa has ...